Valneva ( (VALN) ) has shared an announcement.
On March 31, 2025, Valneva SE announced the submission of a label extension application to the UK MHRA to expand the use of its chikungunya vaccine, IXCHIQ®, to adolescents aged 12 to 17 years. This follows a positive opinion from the EMA and is part of Valneva’s efforts to broaden vaccine access amid ongoing chikungunya outbreaks in several regions. The vaccine, already approved for adults in multiple countries, has shown high efficacy and tolerance in adolescents. Valneva’s strategic partnerships, including a recent agreement with the Serum Institute of India, aim to ensure affordable vaccine supply in low- and middle-income countries, addressing a significant public health issue exacerbated by climate change.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing multiple vaccines from early R&D to approvals. Valneva markets three proprietary travel vaccines, including the world’s first chikungunya vaccine, and is involved in developing vaccine candidates against Lyme disease, Zika virus, and other global public health threats.
YTD Price Performance: 53.81%
Average Trading Volume: 48,691
Technical Sentiment Signal: Hold
Current Market Cap: $576.3M
Find detailed analytics on VALN stock on TipRanks’ Stock Analysis page.